Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Dec-31-20 | Sep-30-20 | Jun-05-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Jun-05-19 |
| 10-K | 10-Q | 8-K | 10-Q | 10-K | 10-Q | 10-Q | 8-K |
Revenues: |
Clinical Research | | | | 2,872.5 | 2,813.0 | | 2,681.5 | |
Data Solutions | | | | 255.5 | 253.3 | | 251.1 | |
Total revenues | | 3,110.1 | | 3,127.9 | 3,066.3 | 2,995.7 | 2,932.6 | |
Revenue growth [+] | | 3.8% | | 8.2% | 6.8% | -24.1% | -13.4% | |
Clinical Research | | | | 8.6% | 7.3% | | | |
Data Solutions | | | | 3.0% | 1.5% | | | |
Cost of goods sold | | 2,065.8 | | 2,254.3 | 2,191.5 | 1,972.9 | 2,132.2 | |
Gross profit | | 1,044.3 | | 873.7 | 874.8 | 1,022.7 | 800.4 | |
Gross margin | | 33.6% | | 27.9% | 28.5% | 34.1% | 27.3% | |
Selling, general and administrative [+] | | 435.8 | | 404.8 | 394.9 | 387.8 | 384.8 | |
Sales and marketing | | 332.3 | | 301.3 | | 291.4 | 288.5 | |
General and administrative | | | | | 103.5 | | | |
EBITDA [+] | | 460.2 | | 468.9 | 479.9 | 473.8 | 415.7 | |
EBITDA growth | | -2.9% | | 16.9% | 21.9% | 57.6% | 34.0% | |
EBITDA margin | | 14.8% | | 15.0% | 15.7% | 15.8% | 14.2% | |
Depreciation | | 34.0 | | 49.1 | 46.3 | 61.6 | 42.8 | |
EBITA | | 426.2 | | 419.8 | 433.6 | 412.2 | 372.9 | |
EBITA margin | | 13.7% | | 13.4% | 14.1% | 13.8% | 12.7% | |
Amortization of intangibles | | 93.5 | | 70.5 | 68.6 | 51.9 | 69.8 | |
EBIT [+] | | 332.7 | | 349.3 | 365.0 | 360.3 | 303.1 | |
EBIT growth | | -7.7% | | 21.1% | 29.6% | 91.2% | 46.1% | |
EBIT margin | | 10.7% | | 11.2% | 11.9% | 12.0% | 10.3% | |
Non-recurring items [+] | | 0.4 | | 1.0 | 1.1 | 1.0 | 0.7 | |
Loss (gain) on sale of assets | | 0.4 | | 1.0 | 1.1 | 1.0 | 0.7 | |
Interest expense | | 50.3 | | 53.1 | 52.0 | 51.4 | 52.8 | |
Interest expense | | 50.3 | | 53.1 | 52.0 | 51.4 | 52.8 | |
Other income (expense), net [+] | | -18.0 | | -4.2 | -6.0 | -0.4 | -6.3 | |
Gain (loss) on foreign currency transactions | | -16.2 | | -0.5 | -2.3 | 2.2 | -5.0 | |
Other | | 0.2 | | 0.3 | 0.2 | -0.2 | -0.3 | |
Pre-tax income | | 264.1 | | 291.1 | 305.9 | 307.6 | 243.2 | |
Income taxes | | 43.5 | | 51.5 | 62.8 | 68.2 | 85.0 | |
Tax rate | | 16.5% | | 17.7% | 20.5% | 22.2% | 35.0% | |
Minority interest | | | | | | | 0.1 | |
Net income | | 220.6 | | 239.6 | 243.0 | 239.7 | 158.2 | |
Net margin | | 7.1% | | 7.7% | 7.9% | 8.0% | 5.4% | |
|
Basic EPS [+] | | $3.47 | | $3.72 | $3.74 | $3.70 | $2.44 | |
Growth | | -6.0% | | 50.6% | 55.5% | 253.5% | 36.4% | |
Diluted EPS [+] | | $3.40 | | $3.64 | $3.66 | $3.60 | $2.37 | |
Growth | | -5.7% | | 52.1% | 57.5% | 258.7% | 38.5% | |
|
|
Shares outstanding (basic) [+] | | 63.5 | | 64.4 | 64.9 | 64.9 | 64.7 | |
Growth | | -2.1% | | 0.0% | 1.6% | 2.1% | 2.5% | |
Shares outstanding (diluted) [+] | | 64.9 | | 65.8 | 66.5 | 66.5 | 66.6 | |
Growth | | -2.4% | | -0.9% | 0.3% | 0.6% | 1.0% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|